Media headlines about Evoke Pharma (NASDAQ:EVOK) have trended somewhat positive on Friday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evoke Pharma earned a news impact score of 0.15 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 48.4662230216965 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of NASDAQ EVOK traded up $0.02 during trading hours on Friday, reaching $3.12. The stock had a trading volume of 63,200 shares, compared to its average volume of 87,285. The firm has a market capitalization of $53.40 million, a price-to-earnings ratio of -3.76 and a beta of 1.47. Evoke Pharma has a twelve month low of $1.85 and a twelve month high of $4.09.
Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. equities analysts anticipate that Evoke Pharma will post -0.47 EPS for the current year.
Several equities research analysts have recently weighed in on EVOK shares. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Friday, August 17th. ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Finally, HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the company a “buy” rating in a research report on Tuesday, June 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.79.
In other news, major shareholder Lvp Gp Iii, Llc bought 500,000 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The stock was acquired at an average cost of $2.35 per share, for a total transaction of $1,175,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 11.94% of the company’s stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Featured Article: Fundamental Analysis and Individual Investors
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.